CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of 2 dosing regimens of oral CellCept
administered as a component of standard immunosuppressive therapy in recipients of kidney
transplants. The anticipated time on study treatment is 3-12 months, and the target sample
size is 100-500 individuals.